PT Indofarma Tbk, together with its subsidiaries, manufactures and sells pharmaceutical products in Indonesia and internationally. The company offers laboratory, pharmaceutical, and health glass equipment; orthopedic and prosthetic equipment; medical and dental equipment; and reparation of Irradiation / X-ray, electromedical and electrotherapy equipment. It also trades in laboratory, pharmaceutical, and medical equipment; and engages in herb infusion, health support, private polyclinic, general practitioner, dentist, and internet trading applications activities. The company was formerly known as PT Indofarma (Persero) Tbk. PT Indofarma Tbk was founded in 1918 and is headquartered in Bekasi, Indonesia. PT Indofarma Tbk is a subsidiary of PT Bio Farma.

Nilai dalam Rupiah. T = triliun, M = miliar. Arahkan kursor ke alur untuk melihat nilai.
Diperbarui: 11/9/2026, 09.26.47
YP are the biggest cumulative sellers (-29 lots), accounting for 100% of total foreign outflow. YP is also the most aggressive right now: 0 lots in 5 days — accelerating outflow on top of the largest position. This is the dominant structural signal across the entire 101-day window.
5-day rate: 0 lots/day vs 20-day average: 0 lots/day. No extreme single-day sessions.
DX is the most aggressive recent buyer: 0 lots in 5 days and 0 lots in 10 days (+0.0%). CC is steadily accumulating (0 lots over 10 days). Combined Pemerintah net position: +248 lots. Latest session: 0 lots. State-linked buying historically caps downside in Indonesian blue chips.
DH added 0 lots (+0.0%) over 10 days. Lokal aggregate 5-day net: 0 lots. Local smart money is adding exposure.